Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review (Q26866246)

scientific article

Language	Label	Description	Also known as
English	Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review	scientific article

Statements

instance of

1 reference

1 reference

Europe PubMed Central

title

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review (English)

1 reference

1 reference

1 reference

Michael S Broder

1

1 reference

stated in

Crossref

language of work or name

1 reference

14 February 2015

1 reference

stated in

PubMed

published in

World Journal of Gastroenterology

1 reference

stated in

PubMed

volume

21

1 reference

stated in

PubMed

page(s)

1945-55

1 reference

stated in

PubMed

issue

6

1 reference

stated in

PubMed

cites work

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4323475

retrieved

21 March 2017

Understanding interobserver agreement: the kappa statistic

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4323475

retrieved

7 April 2017

Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4323475

retrieved

28 September 2017

Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4323475

retrieved

28 September 2017

Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4323475

retrieved

28 September 2017

Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4323475

retrieved

28 September 2017

NANETS consensus guidelines for the diagnosis of neuroendocrine tumor

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4323475

retrieved

28 September 2017

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3748%2FWJG.V21.I6.1945

retrieved

21 January 2018

Somatostatin analogues: treatment of pituitary and neuroendocrine tumors

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3748%2FWJG.V21.I6.1945

retrieved

21 January 2018

Octreotide LAR in carcinoid: how to dose?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3748%2FWJG.V21.I6.1945

retrieved

21 January 2018

Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.3748%2FWJG.V21.I6.1945

retrieved

21 January 2018

High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4323475

retrieved

28 November 2018

Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/25684964

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.3748/WJG.V21.I6.1945

0 references

1 reference

1 reference

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review (Q26866246)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review (Q26866246)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search